ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0735

ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study

Sebastian Klapa1, Henry Nording2, Marlene Ludwig3, Sabrina Arnold4, Khalaf Kridin5, Anja Staehle6, Ralf Ludwig7 and Peter Lamprecht4, 1University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, 2University of Lübeck, Cardioimmunology Research Group, Lübeck, Germany, 3Independent Researcher, Groß Grönau, Germany, 4University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, 55. Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel, 6University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, 7University of Lübeck, Lübeck Institute of Experimental Dermatology, Lübeck, Germany

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Biostatistics, Cardiovascular, Comorbidity, population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: In spite of significantly improved therapy during the last years, long-term morbidity and mortality has remained high in ANCA-associated vasculitis (AAV). The main causes of death within the first year after diagnosis are active vasculitis and infections, followed by cardiovascular disease, malignancies and infections during subsequent years [1,2]. Population-based database and cohort analyses suggest an increased risk for major adverse cardiovascular events (MACE) in AAV [3].

Methods: In this retrospective cohort study, data samples from an electronic health records database of the US-based TriNetX network were analysed. Patients (aged ≥ 18 years) with the diagnostic codes of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) and patients without vasculitis as matched control cohort (1:1) were included. Propensity score matching for demographic variables (age, gender, family history of ischemic heart disease and other disease of the circulatory system, personal history of nicotine dependence) and comorbidity (nicotine dependence, overweight and obesity, dyslipoproteinaemia, arterial hypertension, chronic lower respiratory diseases, chronic kidney disease, neoplasms, diabetes mellitus) was performed to optimize between-group comparability. Hazard ratios (HR) related to death and cardiovascular outcomes (MACE, heart failure, cardiac arrest, myocardial infarction, ischemic stroke, haemorrhagic stroke, pulmonary embolism, cerebrovascular disease, peripheral arterial disease, chronic ischemic heart disease, venous disease, valve disorder, rheumatic heart disease, carditis, conduction disease, deep vein thrombosis) were calculated by univariate Cox regression after analysis of the matched cohort by the Kaplan-Meier method. Pvalues were determined by the Log-rank test.

Results: We identified 20.422 patients with GPA and 5.907 with MPA. The unadjusted and adjusted relative risk (RR) of mortality was increased in GPA (RR 17.87%) and MPA (RR 25.85%) compared to matched controls (GPA: HR: 3.01 P < 0.0001; MPA: HR: 3.01, P < 0.0001; figure 1A and 1B). Compared to GPA, patients with MPA had an increased risk of death within 20 years (MPA vs. GPA: HR: 1.18, P = 0.0006; figure 1B). The risks for all screened cardiovascular events were increased in GPA and MPA compared to matched controls, especially for MACE (GPA: HR 1.94, MPA: HR 2.24, P < 0.0001; figure 1A and 1C) and thromboembolic events (deep vein thrombosis: GPA HR: 2.82, MPA HR: 3.33; pulmonary embolism: GPA HR: 3.01, MPA HR: 3.00; P < 0.0001, figure 1A) and did not differ when adjusted according to gender, disease duration (first 3 years after diagnosis), and age (patients < 46 years, patients > 64 years). Compared to GPA, MPA patients had a higher risk for MACE (MPA vs. GPA: HR: 1.130 P = 0.0011, figure 1C) and peripheral arterial disease (MPA vs. GPA: HR: 1.165, P = 0.0018).

Conclusion: In AAV, the risk of death and cardiovascular events were increased. Compared to GPA, MPA was associated with an increased mortality and risk for MACE and peripheral arterial disease.

 

References:

1.    Arnold S et al. Lancet Rheumatol. 2024

2.    Sánchez Álamo B et al. Nephrol Dial Transplant. 2023

3.    Massicotte-Azarnioch D et al. Clin Kidney J. 2021

Supporting image 1

Figure 1. Risk of Death and Cardiovascular outcomes in AAV A: Increased risk of death and cardiovascular events in GPA (green) and MPA (orange) compared to matched controls; B: Kaplan-Meier survival analysis in AAV compared to matched controls (blue) and between MPA (orange) and GPA (green); C: Kaplan-Meier curve for the occurrence of MACE in AAV compared to matched controls (blue) and between MPA (orange) and GPA (green).


Disclosures: S. Klapa: AbbVie/Abbott, 6, AlphaSigma, 6, AstraZeneca, 1, Galapagos, 1, Novartis, 6, Pfizer, 6; H. Nording: None; M. Ludwig: None; S. Arnold: None; K. Kridin: None; A. Staehle: None; R. Ludwig: None; P. Lamprecht: AbbVie/Abbott, 2, Boehringer-Ingelheim, 6, GlaxoSmithKlein(GSK), 6, Novartis, 6, UCB, 6, Vifor, 5.

To cite this abstract in AMA style:

Klapa S, Nording H, Ludwig M, Arnold S, Kridin K, Staehle A, Ludwig R, Lamprecht P. ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/anca-associated-vasculitis-aav-and-long-term-risk-of-cardiovascular-disease-large-scale-propensity-matched-global-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anca-associated-vasculitis-aav-and-long-term-risk-of-cardiovascular-disease-large-scale-propensity-matched-global-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology